Jan. 9, 2023 A research team has discovered a highly potent biomarker for clinical response to CAR-T cell therapy, describing the prerequisites for optimal use of this novel therapy for lymphoma treatment. The ...
Dec. 22, 2022 Researchers have demonstrated that people suffering from blood cancer have a good immune response to COVID-19 vaccinations. Vaccination protects patients with B-cell lymphoma and multiple myeloma ...
Nov. 22, 2022 A form of blood cancer known as mantle cell lymphoma is critically dependent on a protein that coordinates gene expression, such that blocking its activity with an experimental drug dramatically ...
Oct. 27, 2022 A panel of investigational monoclonal antibodies (mAbs) targeting different sites of the Epstein-Barr virus (EBV) blocked infection when tested in human cells in a laboratory setting. Moreover, one ...
Sep. 8, 2022 Scientists have completed the largest study of families affected by Hodgkin lymphoma and identified novel variants linked to cancer ...
Aug. 24, 2022 An engineer has found a way to determine which patients are likely to respond to #CAR T-cell therapy, saving precious time in treating #lymphoma, which is most responsive to this form of ...
July 14, 2022 A study has found that the addition of brentuximab vedotin to standard chemotherapy treatment improves overall survival in patients with Hodgkin Lymphoma, when compared to the current standard of ...
June 28, 2022 There is considerable variation in the management of mantle cell lymphoma across different clinical settings, and some strategies do not always conform with what might be expected, according to a ...
June 14, 2022 A new study shows that treatment with an immunity boosting protein called interleukin 7 (IL-7) after an infusion of genetically modified T cells causes the cancer-fighting CAR-T cells to grow in ...
June 9, 2022 Researchers have discovered that the interferon gamma receptor (IFNgR) signaling pathway is critical for susceptibility of glioblastoma tumors to killing by CAR T-cell ...
June 3, 2022 Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously ...
May 25, 2022 DNA mutations are essential to the rapid development of an array of antibody-producing immune cells called B cells that collectively can recognize a vast number of specific targets. But this process ...
May 13, 2022 In early research, the oral medication zanubrutinib was found to help most patients with a slow-growing type of cancer known as marginal zone ...
May 12, 2022 A study investigates the reasons for decreasing remission rates for patients with non-Hodgkin lymphoma treated with chimeric antigen receptor-T cell therapy (CAR-T cell ...
Apr. 28, 2022 Researchers identify gene expression signatures in different types of lymph nodes cells that play an active role in the development of ...
Mar. 10, 2022 A recent study followed 515 patients with varying cancers. The goal was to evaluate if patients had an immune response to the Moderna mRNA-1273 vaccine and if that response differed by diagnosis and ...
Feb. 28, 2022 Researchers have shared a comprehensive multiomics study from a rare cohort of 56 patients with transformed CTCL and identified several genomic alterations and oncogenic programs that may be ...
Jan. 12, 2022 There are myriad reasons why cancers develop. By studying genes which are altered in people with lymphoma, a multidisciplinary team of researchers has identified a key mechanism involved in disease ...
Jan. 3, 2022 Aggressive and relatively common lymphomas called diffuse large B cell lymphomas (DLBCLs) have a critical metabolic vulnerability that can be exploited to trick these cancers into starving ...
Dec. 14, 2021 Driving up the immune response at the site of a cancer tumor with nanotechnology may help enhance immunotherapy treatments in advanced stages of the disease, new research in mice ...